What are the latest funding news in the cell therapy market? (July 2026)
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
Cell therapy funding in July 2026 was led by late May and June rounds, because no clearly qualifying July round was found in the public sources checked.
The latest activity shows strong investor interest in CAR-T, in vivo immune programming, iPSC-derived therapies, and regenerative medicine.
Most of the largest recent deals went to companies with clinical assets, commercial launches, or clear paths toward human studies.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
Insights
- CAR-T dominated the latest cell therapy funding news, with 7 of the 12 deals tied to CAR-T or in vivo CAR platforms
- Public-market financings still mattered in cell therapy, with Allogene, Lyell, BrainStorm, and BioRestorative together representing more than $257M
- India appeared twice in the latest cell therapy rounds, showing growing investor interest in affordable CAR-T access and local manufacturing
- China remained active beyond oncology, with iRegene and Regend raising capital for neurodegenerative and organ-regeneration cell therapies
- The biggest private round was CREATE Medicines’ $122M Series B, showing strong appetite for in vivo CAR-T in autoimmune disease and oncology
- Most funded companies were already clinical or commercial, which suggests investors favored cell therapy teams with clear translational progress
- Non-oncology cell therapy was still visible, with cardiovascular, neurodegenerative, musculoskeletal, and organ-regeneration companies in the list
- Valuations were mostly undisclosed, which is common in private biotech rounds but limits direct comparison across cell therapy categories
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Summary table of the latest funding deals in the cell therapy market as of July 2026
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
You can also read our detailed analysis to understand how funding activity in the cell therapy market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the cell therapy market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Immuneel Therapeutics | 8 June 2026 | About $10.5M+ | Series B | Oncology CAR-T & commercial cell therapy |
| Waypoint Bio | 2 June 2026 | $20M | Series A | Solid-tumor CAR-T & in vivo cell therapy |
| iRegene Therapeutics | 1 June 2026 | About $31M | C1 financing | Neurodegenerative iPSC-derived cell therapy |
| Secretome Therapeutics | 27 May 2026 | $30M | Series A | Cardiovascular regenerative cell therapy |
| Cellogen Therapeutics | 18 May 2026 | About $2.0M to $2.3M | Strategic investment | Oncology CAR-T & affordable cell therapy |
| CREATE Medicines | 14 May 2026 | $122M | Series B | In vivo CAR-T & autoimmune cell therapy |
| Vivacta Bio | 29 April 2026 | Over $50M | Series A and Series A+ | In vivo CAR-T & autoimmune cell therapy |
| Allogene Therapeutics | 16 April 2026 | $200.4M | Public offering | Allogeneic CAR-T & oncology cell therapy |
| Lyell Immunopharma | 9 March 2026 | $50M | Equity private placement tranche | Oncology CAR-T & next-generation cell therapy |
| BrainStorm Cell Therapeutics | 26 February 2026 | $2M | Strategic private placement | Neurodegenerative stem-cell therapy |
| BioRestorative Therapies | 13 February 2026 | $5M | Public offering | Musculoskeletal regenerative cell therapy |
| Regend Therapeutics | 11 February 2026 | About $48M to $51M | Series C | Organ-regeneration cell therapy |
All the latest funding deals during in the cell therapy market as of July 2026
Immuneel Therapeutics raised about $10.5M in June 2026
When was it?
The deal was announced on 8 June 2026.
Who are they?
Immuneel Therapeutics is an India-based cell and gene therapy company commercializing affordable CAR-T cancer treatments, including Qartemi.
Geographical focus?
Immuneel Therapeutics is focused on India first, with planned expansion across Asia Pacific and the Middle East.
Why do we include them in the cell therapy market?
Immuneel Therapeutics belongs in the cell therapy market because CAR-T therapy is central to the company, under oncology CAR-T and commercial cell therapy.
What is the company stage?
Immuneel Therapeutics is commercial and growth-stage, because Qartemi has launched and the company is scaling manufacturing and access.
How much did they raise?
Immuneel Therapeutics raised over ₹100 crore, which was about $10.5M.
What round is it?
The Immuneel Therapeutics round was a Series B financing.
Why did they raise?
Immuneel Therapeutics raised to scale GMP manufacturing, commercialize Qartemi, expand the pipeline, and enter international markets.
Waypoint Bio raised $20M in June 2026
When was it?
The deal was announced on 2 June 2026.
Who are they?
Waypoint Bio uses AI, spatial biology, and screening to design in vivo CAR-T therapies for solid tumors.
Geographical focus?
Waypoint Bio is based in New York, with clinical entry expected in China in late 2026.
Why do we include them in the cell therapy market?
Waypoint Bio belongs in the cell therapy market because the lead program is an in vivo CAR-T therapy for solid tumors.
What is the company stage?
Waypoint Bio is preclinical to clinical-entry stage, because WAY-103 is being advanced toward first human testing.
How much did they raise?
Waypoint Bio raised $20M in this round.
What round is it?
The Waypoint Bio round was a Series A financing.
Why did they raise?
Waypoint Bio raised to move WAY-103 toward human testing, expand the platform, and build clinical development capabilities.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
iRegene Therapeutics raised about $31M in June 2026
When was it?
The deal was announced on 1 June 2026.
Who are they?
iRegene Therapeutics develops iPSC-derived cell therapies for Parkinson’s disease, multiple system atrophy, and retinal degeneration.
Geographical focus?
iRegene Therapeutics is focused on China, while its lead Parkinson’s program has entered Phase II trials in China and the U.S.
Why do we include them in the cell therapy market?
iRegene Therapeutics belongs in the cell therapy market because its core products are iPSC-derived therapeutic cells for serious diseases.
What is the company stage?
iRegene Therapeutics is clinical-stage, with a Parkinson’s candidate in Phase II and another neurodegenerative candidate cleared for trials.
How much did they raise?
iRegene Therapeutics raised CNY210M, which was about $31M.
What round is it?
The iRegene Therapeutics round was a C1 financing.
Why did they raise?
iRegene Therapeutics raised to advance clinical programs, scale manufacturing, upgrade the platform, and support global development.
Secretome Therapeutics raised $30M in May 2026
When was it?
The deal was announced on 27 May 2026.
Who are they?
Secretome Therapeutics develops neonatal cardiac progenitor cell therapies, led by STM-01 for serious cardiomyopathies.
Geographical focus?
Secretome Therapeutics is focused on the U.S., starting with rare and serious cardiovascular diseases.
Why do we include them in the cell therapy market?
Secretome Therapeutics belongs in the cell therapy market because STM-01 is a therapeutic progenitor-cell product.
What is the company stage?
Secretome Therapeutics is clinical-stage and is moving STM-01 toward pivotal Phase 2 and Phase 3 development.
How much did they raise?
Secretome Therapeutics raised $30M in this round.
What round is it?
The Secretome Therapeutics round was a Series A financing.
Why did they raise?
Secretome Therapeutics raised to advance STM-01 toward pivotal trials in Duchenne-associated cardiomyopathy and support its broader pipeline.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Cellogen Therapeutics raised about $2.0M to $2.3M in May 2026
When was it?
The deal was announced on 18 May 2026.
Who are they?
Cellogen Therapeutics develops CAR-T and gene therapy programs for cancers and blood disorders.
Geographical focus?
Cellogen Therapeutics is focused on India, especially lower-cost advanced therapies for local patients.
Why do we include them in the cell therapy market?
Cellogen Therapeutics belongs in the cell therapy market because CAR-T therapy development is a core company focus.
What is the company stage?
Cellogen Therapeutics is pre-Phase 1 to clinical-entry stage, with CAR-T programs moving toward human trials.
How much did they raise?
Cellogen Therapeutics raised ₹20 crore, or roughly $2.0M to $2.3M depending on exchange rate.
What round is it?
The Cellogen Therapeutics round was described as a strategic investment, not a named Series round.
Why did they raise?
Cellogen Therapeutics raised to advance CAR-T clinical programs, grow its gene therapy pipeline, and strengthen GMP and regulatory capabilities.
CREATE Medicines raised $122M in May 2026
When was it?
The deal was announced on 14 May 2026.
Who are they?
CREATE Medicines develops in vivo CAR therapies that program immune cells inside the patient using mRNA-LNP technology.
Geographical focus?
CREATE Medicines is U.S.-based and develops therapies for autoimmune disease and oncology.
Why do we include them in the cell therapy market?
CREATE Medicines belongs in the cell therapy market because its platform creates engineered immune-cell therapies in vivo.
What is the company stage?
CREATE Medicines is clinical-stage, with more than 50 patients dosed across in vivo CAR programs.
How much did they raise?
CREATE Medicines raised $122M in this round.
What round is it?
The CREATE Medicines round was a Series B financing.
Why did they raise?
CREATE Medicines raised to advance CD19 autoimmune work, expand CD19 x BCMA programs, and keep moving oncology programs forward.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
Vivacta Bio raised over $50M in April 2026
When was it?
The deal was announced on 29 April 2026.
Who are they?
Vivacta Bio is a Shanghai company developing in vivo CAR-T therapies, led by GT801.
Geographical focus?
Vivacta Bio is focused on China, with global clinical and operating ambitions.
Why do we include them in the cell therapy market?
Vivacta Bio belongs in the cell therapy market because its core product is an in vivo CAR-T therapy.
What is the company stage?
Vivacta Bio is early clinical-stage, with early human data reported for GT801.
How much did they raise?
Vivacta Bio raised over $50M through the combined financing.
What round is it?
The Vivacta Bio financing combined Series A and Series A+ rounds.
Why did they raise?
Vivacta Bio raised to advance GT801 trials, support regulatory submissions, expand R&D, and accelerate global expansion.
Allogene Therapeutics raised $200.4M in April 2026
When was it?
The deal was announced as closed on 16 April 2026.
Who are they?
Allogene Therapeutics develops off-the-shelf allogeneic CAR-T therapies for cancer and autoimmune disease.
Geographical focus?
Allogene Therapeutics is based in South San Francisco and works on U.S. and global clinical development.
Why do we include them in the cell therapy market?
Allogene Therapeutics belongs in the cell therapy market because allogeneic CAR-T product development is the core business.
What is the company stage?
Allogene Therapeutics is late clinical-stage, with pivotal oncology programs and autoimmune programs.
How much did they raise?
Allogene Therapeutics raised $200.4M in gross proceeds.
What round is it?
The Allogene Therapeutics round was an underwritten public offering, not a venture Series round.
Why did they raise?
Allogene Therapeutics raised to fund clinical trials, R&D, G&A, capital expenditures, and general corporate purposes.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Lyell Immunopharma raised $50M in March 2026
When was it?
The deal was announced on 9 March 2026.
Who are they?
Lyell Immunopharma develops next-generation CAR-T therapies for hematologic malignancies and solid tumors.
Geographical focus?
Lyell Immunopharma is focused on U.S. oncology development from South San Francisco.
Why do we include them in the cell therapy market?
Lyell Immunopharma belongs in the cell therapy market because its pipeline is built around CAR-T cell therapies.
What is the company stage?
Lyell Immunopharma is late clinical-stage, with ronde-cel in pivotal development for relapsed or refractory large B-cell lymphoma.
How much did they raise?
Lyell Immunopharma raised $50M in this tranche, bringing the broader private placement to about $100M.
What round is it?
The Lyell Immunopharma round was the second tranche of an equity private placement.
Why did they raise?
Lyell Immunopharma raised after a clinical milestone to extend runway and support CAR-T development.
BrainStorm Cell Therapeutics raised $2M in February 2026
When was it?
The second placement was announced on 26 February 2026.
Who are they?
BrainStorm Cell Therapeutics develops autologous adult stem-cell therapies for neurodegenerative diseases, led by NurOwn for ALS.
Geographical focus?
BrainStorm Cell Therapeutics is mainly focused on U.S. clinical and regulatory development for ALS.
Why do we include them in the cell therapy market?
BrainStorm Cell Therapeutics belongs in the cell therapy market because NurOwn is an autologous mesenchymal stem-cell therapy.
What is the company stage?
BrainStorm Cell Therapeutics is late clinical-stage, with a completed Phase 3 and a planned Phase 3b confirmatory study.
How much did they raise?
BrainStorm Cell Therapeutics raised $2M total in February 2026.
What round is it?
The BrainStorm Cell Therapeutics round was a strategic private placement.
Why did they raise?
BrainStorm Cell Therapeutics raised to support near-term regulatory and clinical objectives for NurOwn.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
BioRestorative Therapies raised $5M in February 2026
When was it?
The deal was announced as closed on 13 February 2026.
Who are they?
BioRestorative Therapies develops stem-cell-based therapies, led by BRTX-100 for painful lumbosacral disc disorders.
Geographical focus?
BioRestorative Therapies is focused on U.S. regenerative medicine development.
Why do we include them in the cell therapy market?
BioRestorative Therapies belongs in the cell therapy market because BRTX-100 is an autologous mesenchymal stem-cell product.
What is the company stage?
BioRestorative Therapies is late clinical-stage, with BRTX-100 progressing through clinical development.
How much did they raise?
BioRestorative Therapies raised $5M in gross proceeds.
What round is it?
The BioRestorative Therapies round was a public offering of common stock or pre-funded warrants plus warrants.
Why did they raise?
BioRestorative Therapies raised to fund BRTX-100 trials, ThermoStem preclinical R&D, working capital, and general corporate purposes.
Regend Therapeutics raised about $48M to $51M in February 2026
When was it?
The deal was announced on 11 February 2026.
Who are they?
Regend Therapeutics develops stem and progenitor-cell regenerative therapies for organ repair, including lung and kidney disease programs.
Geographical focus?
Regend Therapeutics is focused on China, especially COPD, IPF, and chronic kidney disease.
Why do we include them in the cell therapy market?
Regend Therapeutics belongs in the cell therapy market because the core assets are stem and progenitor-cell therapeutic products for organ regeneration.
What is the company stage?
Regend Therapeutics is clinical-stage to clinical-translation stage, including a kidney progenitor cell therapy in Phase I trials in China.
How much did they raise?
Regend Therapeutics raised RMB350M, or about $48M to $51M depending on exchange rate.
What round is it?
The Regend Therapeutics round was a Series C financing.
Why did they raise?
Regend Therapeutics raised to accelerate clinical translation of core cell products and prepare for larger-scale commercialization.
Related blog posts
- How strong is fundraising in the cell therapy market right now?
- What is the latest news in the cell therapy market?
- What is the true size of the cell therapy market?
- How funding activity has evolved in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- A complete list of funding deals in the cell therapy market
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- A complete list of business models in the cell therapy market
